D3 Bio (Wuxi) Co., Ltd
D3 Bio (Wuxi) Co., Ltd
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations | Advanced Solid Tumors With MAPK Pathway Mutations | Recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT05886920 | |
| Study of D3L-002 in Subjects With Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 | 2026-09-18 | NCT07667842 | |
| A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation | KRAS P.G12C | Recruiting | Phase 1 / Phase 2 | 2026-09-15 | NCT05410145 | |
| A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation. | KRAS P.G12D | Recruiting | Phase 1 | 2026-09-08 | NCT07456046 | |
| A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors | HER-2 Positive Advanced Solid Tumors | Recruiting | Phase 1 | 2026-08-28 | NCT05957536 |